ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 654,61
0,70%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Vaxcyte Inc (PCVX)

  7. Vaxcyte Inc (PCVX) Actualités

PCVX

Vaxcyte (PCVX)

Vaxcyte Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PCVX
DateHeureSourceTitreSymboleSociété
10/06/202422h19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PCVXVaxcyte Inc
10/06/202422h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PCVXVaxcyte Inc
03/06/202422h02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PCVXVaxcyte Inc
24/05/202423h05Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PCVXVaxcyte Inc
08/05/202422h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PCVXVaxcyte Inc
08/05/202422h05GlobeNewswire Inc.Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
02/04/202422h05GlobeNewswire Inc.Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:PCVXVaxcyte Inc
04/03/202414h30GlobeNewswire Inc.Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in InfantsNASDAQ:PCVXVaxcyte Inc
27/02/202422h58Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PCVXVaxcyte Inc
27/02/202422h01GlobeNewswire Inc.Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
15/02/202422h05GlobeNewswire Inc.Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024NASDAQ:PCVXVaxcyte Inc
03/02/202400h39GlobeNewswire Inc.Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:PCVXVaxcyte Inc
01/02/202422h05GlobeNewswire Inc.Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceNASDAQ:PCVXVaxcyte Inc
31/01/202423h26Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PCVXVaxcyte Inc
31/01/202405h37GlobeNewswire Inc.Vaxcyte Announces Pricing of $750 Million Public OfferingNASDAQ:PCVXVaxcyte Inc
30/01/202422h01GlobeNewswire Inc.Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:PCVXVaxcyte Inc
29/01/202414h30GlobeNewswire Inc.Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and OlderNASDAQ:PCVXVaxcyte Inc
16/01/202422h01GlobeNewswire Inc.Vaxcyte Appoints Whitney Jones as Chief People OfficerNASDAQ:PCVXVaxcyte Inc
04/01/202422h01GlobeNewswire Inc.Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) FranchiseNASDAQ:PCVXVaxcyte Inc
05/12/202300h35GlobeNewswire Inc.VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) CandidateNASDAQ:PCVXVaxcyte Inc
29/11/202322h46Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PCVXVaxcyte Inc
28/11/202314h30GlobeNewswire Inc.Vaxcyte Appoints Jacks Lee to Board of DirectorsNASDAQ:PCVXVaxcyte Inc
27/11/202322h00GlobeNewswire Inc.Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine CandidatesNASDAQ:PCVXVaxcyte Inc
09/11/202314h30GlobeNewswire Inc.Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in AdultsNASDAQ:PCVXVaxcyte Inc
06/11/202322h03GlobeNewswire Inc.Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
31/10/202321h05GlobeNewswire Inc.Vaxcyte to Present at Upcoming Investor ConferencesNASDAQ:PCVXVaxcyte Inc
19/10/202315h29Dow Jones NewsVaxcyte Gets FDA Go-Ahead on Pneumococcal Vaccine ApplicationNASDAQ:PCVXVaxcyte Inc
19/10/202314h30GlobeNewswire Inc.Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in AdultsNASDAQ:PCVXVaxcyte Inc
16/10/202314h00GlobeNewswire Inc.Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)NASDAQ:PCVXVaxcyte Inc
19/09/202322h05GlobeNewswire Inc.Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:PCVXVaxcyte Inc
 Showing the most relevant articles for your search:NASDAQ:PCVX

Dernières Valeurs Consultées

EU
EIAI
EssilorLuxottica SA 0.25...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés